Takeda Pharmaceutical Company Limited
TAK · NYSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $7,159,101,492 | $6,486,041,177 | $6,788,721,923 | $5,447,459,376 |
| - Cash | $385,113,000 | $457,800,000 | $533,530,000 | $849,695,000 |
| + Debt | $4,515,265,000 | $4,843,752,000 | $4,382,341,000 | $4,345,411,000 |
| Enterprise Value | $11,289,253,492 | $10,871,993,177 | $10,637,532,923 | $8,943,175,376 |
| Revenue | $4,581,551,000 | $4,263,762,000 | $4,027,478,000 | $3,569,006,000 |
| % Growth | 7.5% | 5.9% | 12.8% | – |
| Gross Profit | $3,001,334,000 | $2,832,257,000 | $2,783,406,000 | $2,462,160,000 |
| % Margin | 65.5% | 66.4% | 69.1% | 69% |
| EBITDA | $1,210,512,000 | $1,143,936,000 | $1,284,067,000 | $1,183,213,000 |
| % Margin | 26.4% | 26.8% | 31.9% | 33.2% |
| Net Income | $107,928,000 | $144,067,000 | $317,017,000 | $230,059,000 |
| % Margin | 2.4% | 3.4% | 7.9% | 6.4% |
| EPS Diluted | 33.62 | 45.58 | 100.97 | 72.94 |
| % Growth | -26.2% | -54.9% | 38.4% | – |
| Operating Cash Flow | $1,057,182,000 | $716,344,000 | $977,156,000 | $1,123,105,000 |
| Capital Expenditures | -$200,795,000 | -$480,730,000 | -$633,689,000 | -$186,037,000 |
| Free Cash Flow | $856,387,000 | $235,614,000 | $343,467,000 | $937,068,000 |